Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (6810)	7/26/1998 10:24:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Why talk about sepsis? Wall Street hates sepsis companies! NO! Wall Street hates any company it has invested in that has a drug failure. Wall Street does not care that an oil company almost went broke with a string of dry exploration wells if an important big hit has just been made. The past is just so much useless history. If a bad luck biotech hits it big with an approval, Wall Street will be there. Sepsis is an important indication. Meningococcemia is sepsis. And as an indication it's important to remember that the victims were healthy until they came down with the disease. They were not trauma victims nor did they have some chronic disease. This means a better chance of demonstrating that Neuprex works. In other populations if the patient dies from some other cause it seems a bit hard to prove that the Neuprex was working just fine. That has always been sited as a problem with trauma trials. It also explains in part why the current trauma trials principal focus is on the narrower indicator of respiratory problems.